Pharsight

Sprycel patents expiration

SPRYCEL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491725 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Mar, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680103 BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Feb, 2025

(1 year, 4 months from now)

US8680103

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Aug, 2025

(1 year, 10 months from now)

US7491725

(Pediatric)

BRISTOL MYERS SQUIBB Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Sep, 2026

(2 years from now)

Sprycel is owned by Bristol Myers Squibb.

Sprycel contains Dasatinib.

Sprycel has a total of 4 drug patents out of which 0 drug patents have expired.

Sprycel was authorised for market use on 28 June, 2006.

Sprycel is available in tablet;oral dosage forms.

The generics of Sprycel are possible to be released after 28 September, 2026.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 21, 2025
Pediatric Exclusivity (PED) Jun 21, 2026

Drugs and Companies using DASATINIB ingredient

Market Authorisation Date: 28 June, 2006

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SPRYCEL before it's drug patent expiration?
More Information on Dosage

SPRYCEL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic